FDA Announces Major Recall of Popular Coffee
So, what's the definition of a recall? According to the Food and Drug Administration (FDA), a recall is a "method of removing or correcting products that are in violation of laws administered by the FDA."
The FDA adds that a "recall is a voluntary action that takes place because manufacturers and distributors carry out their responsibility to protect the public health and well-being from products that present a risk of injury or gross deception or are otherwise defective."
Now, an instant coffee is being recalled due to potential glass fragments.
A Voluntary Recall of Coffee Over Glass Fragments
Dollar General has issued a voluntary recall in 46 U.S. states due to concerns of glass exposure in jars of its Clover Valley Instant Coffee. on Aug. 11, Dollar General released a voluntary recall notice on its website and said that a customer's report of possible glass in the product is what sparked recall.
The statement adds, "Dollar General is actively investigating the source of the glass contamination and apologizes for any inconvenience caused by this product issue."
The FDA also released information about the recall. "Ingesting glass fragments may cause injury to the consumer, and these injuries may include damage to teeth, laceration of the mouth and throat, or perforation of the intestine," they stated. The good news is that no illnesses or injuries have been reported so far.
According to the FDA notice, customers who purchased the coffee are encouraged to throw it out and contact Dollar General either via email at customercare@dollargeneral.com or by phone at 1-888-309-9030 from 6 a.m. to 1 a.m. CST seven days a week to request a full refund of the purchase price, including any tax.
The recalled Clover Valley Instant Coffee was sold and distributed in Dollar General retail stores between July 9 and 21, 2025. More information with specific lot numbers can be found via the Dollar General notice.FDA Announces Major Recall of Popular Coffee first appeared on Men's Journal on Aug 13, 2025
Solve the daily Crossword
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
6 minutes ago
- CNBC
Novo Nordisk's Wegovy receives FDA approval to treat serious liver disease
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on Novo Nordisk, what new FDA approval on its Wegovy drug means for sales, and much more.
Yahoo
24 minutes ago
- Yahoo
Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Disease
On Saturday, the U.S. Food and Drug Administration (FDA) approved an additional indication for Novo Nordisk A/S' (NYSE:NVO) Wegovy (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity. The accelerated approval is based on part 1 of the ESSENCE trial, in which Wegovy demonstrated a statistically significant and superior improvement in liver fibrosis with no worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis compared to placebo. The clinical data from ESSENCE showed that at week 72, 36.8% of people treated with Wegovy achieved improvement in liver fibrosis with no worsening of steatohepatitis compared to 22.4% treated with placebo. 62.9% of people treated with Wegovy achieved resolution of steatohepatitis with no worsening of liver fibrosis compared to 34.3% treated with part 2, the objective is to demonstrate that treatment with semaglutide 2.4 mg lowers the risk of liver-related clinical events compared to placebo in adults with MASH and moderate to advanced liver fibrosis at 240 weeks. Part 2 of the ESSENCE trial will continue with the expected readout in 2029. The approval marks a positive development for Novo Nordisk as the European company faces downward sales for its GLP-1 products due to slower-than-expected penetration of its branded GLP-1 treatments and persistent use of compounded GLP-1 alternatives. Novo Nordisk projects 2025 sales growth to be in the range of 8-14% at constant exchange rates, a notable reduction from its earlier forecast of 13-21%. In May, Health Canada accepted for review, under the Priority Review policy, its supplemental new drug submission (sNDS) for semaglutide 2.4 mg, a once-weekly therapy for MASH. In March 2024, the FDA approved a label expansion for Wegovy based on a supplemental New Drug Application for reducing risks of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal heart attack (myocardial infarction), or non-fatal stroke in adults with either overweight or obesity and established cardiovascular disease (CVD). The approval was based on the SELECT cardiovascular outcomes trial, which demonstrated that Wegovy statistically significantly reduced the risk of MACE by 20% compared to placebo when added to standard of care. The findings from SELECT also showed that risk reductions in MACE were achieved in up to five years. In addition, the label was updated to include data from SELECT showing a risk reduction in cardiovascular death by 15% and a risk reduction of death from any cause by 19%, compared to placebo. In March 2024, Madrigal Pharmaceuticals Inc.'s (NASDAQ:MDGL) Rezdiffra (resmetirom) became the first FDA-approved treatment for patients with liver scarring due to fatty liver disease. The FDA granted accelerated approval, and continued approval for this indication may be contingent upon verification and description of clinical benefit in ongoing confirmatory trials. Price Action: NVO shares climbed 7.14% to $56.15, up $3.74, in after-hours trading on Friday. Read Next:Photo by Tobias Arhelger via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? NOVO NORDISK (NVO): Free Stock Analysis Report This article Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Disease originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Novo Nordisk Shares Rise on U.S. Approval of Wegovy for Liver Disease
Novo Nordisk (NVO, Financials) shares climbed nearly 5% Monday after the U.S. Food and Drug Administration granted accelerated approval for its weight-loss drug Wegovy to treat metabolic dysfunction-associated steatohepatitis in adults with moderate to advanced liver fibrosis. Warning! GuruFocus has detected 1 Warning Sign with NVO. The approval makes Wegovy the first GLP-1 therapy cleared for MASH, a progressive liver condition affecting about 5% of U.S. adults, according to the American Liver Foundation. The drug was approved for use alongside a reduced-calorie diet and increased physical activity. Novo Nordisk said the decision was supported by the first phase of its ESSENCE trial, which showed Wegovy patients had statistically significant improvements in liver fibrosis compared to placebo. About 63% of participants receiving Wegovy achieved resolution of steatohepatitis without worsening fibrosis, compared with 34% in the placebo group. More than one-third of Wegovy patients also saw improvement in fibrosis without worsening steatohepatitis, versus 22% on placebo. The second phase of the trial is expected in 2029. The company said Wegovy is immediately available in the U.S. for MASH. The only other FDA-approved treatment for the disease is Madrigal Pharmaceuticals' (MDGL, Financials) Rezdiffra, cleared in 2024. Novo Nordisk shares were up 5.46% in London trading as of 10:43 a.m. This article first appeared on GuruFocus.
